title: Dual paraneoplastic syndromes: small cell lung carcinoma-related oncogenic osteomalacia, and syndrome of inappropriate antidiuretic hormone secretion: report of a case and review of the literature.
abstract: Acquired isolated renal phosphate wasting associated with a tumor, known as oncogenic osteomalacia or tumor-induced osteomalacia, is a rare paraneoplastic syndrome caused by overproduction of fibroblast growth factor 23. Oncogenic osteomalacia is usually associated with benign mesenchymal tumors. Syndrome of inappropriate antidiuretic hormone secretion (SIADH), on the other hand, is a common paraneoplastic syndrome caused by small cell carcinoma (SCC). Concomitant oncogenic osteomalacia and SIADH associated with SCC is very rare with only 4 other cases reported in the literature. The authors report a case of small cell lung cancer (SCLC)-related renal wasting hypophosphatemia and concurrent SIADH, and review the literature reporting 9 other cases of SCC associated with oncogenic osteomalacia. Almost half of reported cases of renal phosphate wasting associated with SCC concomitantly presented with SIADH. These cases had initial serum phosphorus level lower and survival periods shorter than those without SIADH. This rare combination of a dual paraneoplastic syndrome and low serum phosphorus may be a poor prognostic sign. In addition, both renal phosphate wasting and SIADH usually occur in a short period of time before identification of SCC. Therefore, renal wasting hypophosphatemia with concomitant SIADH/hyponatremia should prompt a search for SCC rather than a benign mesenchymal tumor.
authors: Department of Medicine, John A. Burns School of Medicine, University of Hawai'i, Honolulu, HI 96813, USA. ekamol@hawaii.edu
authors: Ekamol
authors: E
authors: Tantisattamo
authors: Roland C K
authors: RC
authors: Ng
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002945:Cisplatin / Q000008:administration & dosage; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D017809:Fatal Outcome; D006073:Gout / Q000150:complications; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications; D006973:Hypertension / Q000150:complications; D017674:Hypophosphatemia / Q000209:etiology; D007177:Inappropriate ADH Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D000077146:Irinotecan; D008113:Liver Neoplasms / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000556:secondary; D008175:Lung Neoplasms / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D010018:Osteomalacia / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D010257:Paraneoplastic Syndromes / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D012307:Risk Factors; D055752:Small Cell Lung Carcinoma / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000556:secondary
chemical_list: D000077146:Irinotecan; D002945:Cisplatin; D002166:Camptothecin